STNG:NYSEScorpio Tankers Inc. Analysis
Data as of 2026-05-03 - not real-time
$82.99
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Scorpio Tankers is trading at $82.99, comfortably above its 20‑day ($77.03) and 50‑day ($74.93) moving averages and well above the 200‑day level ($60.56), indicating a strong bullish trend. The MACD histogram remains positive (0.60) and the RSI sits at 68, suggesting momentum is still intact but edging toward overbought territory. Valuation metrics reinforce the case: a trailing P/E of 11.8 is far below the industry average of 22.7, and the stock offers a 2.01% dividend yield with a modest 23% payout ratio, pointing to sustainable cash‑flow coverage. Recent corporate actions—closing a $375 million convertible senior note offering and repurchasing 1.34 million shares at $74.36—have bolstered liquidity while adding a convertible‑debt element to the capital structure.
Looking ahead, analysts project a median price target of $90, implying roughly a 4–5% upside, and the DCF model suggests a fair value near $151, underscoring long‑term upside potential if market sentiment improves. The company’s revenue grew 24% year‑over‑year, margins remain healthy (gross 65%, operating 35%), and free cash flow exceeds $213 million, supporting both dividend continuation and debt service. However, a high 30‑day volatility of 38% and a leveraged balance sheet (debt‑to‑equity ~19) temper enthusiasm, making the stock a compelling but moderately risky play.
Looking ahead, analysts project a median price target of $90, implying roughly a 4–5% upside, and the DCF model suggests a fair value near $151, underscoring long‑term upside potential if market sentiment improves. The company’s revenue grew 24% year‑over‑year, margins remain healthy (gross 65%, operating 35%), and free cash flow exceeds $213 million, supporting both dividend continuation and debt service. However, a high 30‑day volatility of 38% and a leveraged balance sheet (debt‑to‑equity ~19) temper enthusiasm, making the stock a compelling but moderately risky play.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price above key moving averages and bullish MACD
- Attractive dividend yield with low payout ratio
- Recent capital raise and share repurchase improving balance sheet
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to peers (P/E 11.8 vs industry 22.7)
- Strong revenue growth and solid operating margins
- Projected upside to median target price of $90
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Long‑term DCF fair value suggests significant upside if market sentiment improves
- High volatility and leverage increase downside risk
- Convertible note issuance could dilute equity if converted
Key Metrics & Analysis
Financial Health
Revenue Growth23.90%
Profit Margin36.70%
P/E Ratio11.8
ROE11.35%
ROA4.99%
Debt/Equity19.36
P/B Ratio1.2
Op. Cash Flow$491.2M
Free Cash Flow$213.2M
Industry P/E22.7
Technical Analysis
TrendBullish
RSI67.9
Support$72.34
Resistance$83.10
MA 20$77.03
MA 50$74.93
MA 200$60.56
MACDBullish
VolumeDecreasing
Fear & Greed Index91.09
Valuation
Fair Value$150.85
Target Price$86.67
Upside/Downside4.43%
GradeUndervalued
TypeBlend
Dividend Yield2.01%
Risk Assessment
Beta0.25
Volatility38.19%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.